RCT | Nivolumab vs. nivolumab plus docetaxel for previously treated advanced or recurrent immune checkpoint inhibitor-naïve non-small-cell lung cancer. 25 Aug, 2022 | 11:48h | UTC A randomized comparison of nivolumab versus nivolumab + docetaxel for previously treated advanced or recurrent ICI-naïve non-small-cell lung cancer: TORG1630 – Clinical Cancer Research